Multiple Myeloma

Multiple myeloma—a cancer that forms in a type of blood cell called a plasma cell—is a chronic disease that requires ongoing care and monitoring. Our team of specialists partners with you throughout diagnosis and treatment. We use sophisticated diagnostic and genetic tests, some of which were developed at NYU Langone, to guide treatment planning. We also draw upon recent medical advances to provide you with customized therapy. Our doctors have conducted clinical trials to help establish a number of the medications in use today, including immune therapies and targeted medications.

Clinical Trials and Research Studies

Phase 1

An open-label phase I multi-center study to determine the recommended dose of the chimeric antigen receptor T-cell treatment CYAD-211 after a non-myeloablative preconditioning chemotherapy in multiple myeloma patients with relapsed or refractory disease

Learn More

Phase 5

A MULTI-CENTER OPEN LABEL PHASE 1/2 STUDY OF CYT-0851 AN ORAL RAD51 INHIBITOR IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES AND ADVANCED SOLID TUMORS

Learn More

Phase 3

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Learn More

Phase 2

Phase 2 Trial of Intensive Chemo-immunotherapy with Carfilzomib Lenalidomide Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the context of salvage autologous hematopoietic cell transplantation.

Learn More